Top-Foren
|
|
|
|
|---|---|---|
| Gesamt | 78 | 953 |
| Börse | 62 | 612 |
| Talk | 7 | 224 |
| Hot-Stocks | 9 | 117 |
| Blockchain | 7 | 111 |
| DAX | 0 | 36 |
Nanotechnologie - Noch kann man einsteigen :-)
|
Seite 2 von 7
neuester Beitrag: 25.04.21 13:23
|
||||
| eröffnet am: | 08.05.03 00:31 von: | Dr.UdoBroem. | Anzahl Beiträge: | 155 |
| neuester Beitrag: | 25.04.21 13:23 von: | Nicoleyiwga | Leser gesamt: | 100727 |
| davon Heute: | 21 | |||
| bewertet mit 2 Sternen |
||||
|
|
||||
Thread abonnieren
|
--button_text--
interessant
|
|
witzig
|
|
gut analysiert
|
|
informativ
|
Source: Harris & Harris Group, Inc.
Nanotechnologies, Inc. Announces Development Agreement with Essilor
Tuesday June 3, 1:43 pm ET
NEW YORK--(BUSINESS WIRE)--June 3, 2003--Harris & Harris Group noted today that Nanotechnologies, Inc. (www.nanoscale.com), a technology leader in high-performance nanoparticles, has announced that it has entered into a development agreement for eyewear applications with Essilor, the world leader in ophthalmic lenses. Harris & Harris Group owns a fully diluted 6.48% interest in Nanotechnologies, Inc.
Optionen
Mon May 12, 6:00 AM
ET
by Tyson Freeman
Most startups seeking venture financing these days face anuphill battle. The process is longer and more rigorous, and drastic down rounds are often necessary to coax new investors to come across.
That's not the case, however, for Nanosys Inc. The Palo Alto, Calif., company announced on April 24 that it completed a $30 million first closing of its second-round financing. According to several of the investors who managed to win a spot in syndicate, no fewer than 65 investors lined up for a piece of the company,.
The competition helped bid the company's valuation up nearly 75%, says Nanosys CEO Larry Bock.
For its second round, Nanosys settled on strategic investors CDIB BioScience Ventures, Chiao Tung Bank and China Development Industrial Bank, all of Taipei; Quanta Computer Inc. of Taoyuan, Taiwan; SAIC Venture Capital Corp. of Las Vegas; and two venture firms that specialize in nanotechnology, Harris & Harris Group Inc. and Lux Capital LLC, both of New York.
"With the group of top scientists and business minds involved and the platform approach taken by the company ... the entire package is very compelling," says Lux Capital managing partner Josh Wolfe.
Returning investors in the round were Arch Venture Partners of Chicago, CW Group and Venrock Associates of New York, Polaris Venture Partners LP of Seattle, Prospect Venture Partners of Palo Alto and Alexandria Real Estate Equities Inc. of Pasadena, Calif.
The company plans to develop what it calls nanowires, nanotubes and nanodots that will eventually find commercial uses in a broad range of industrial, high-technology and biotechnology products. (A nanometer is a billionth of a meter, a fraction of the width of a human hair.) With control of 75 nanotechnology-related patents, Nanosys plans to strike partnerships with a handful of top corporate players to help develop commercially viable products.
The strong interest and spike in valuation is reminiscent of the dot-com boom without the twenty-something CEO and back-of-the-envelope business plan. And some independent observers caution that, for all the enthusiasm for nanotechnology, the company still faces some serious hurdles. For instance, there are still significant challenges left in moving from scientific research to commercialized products, says Neal Gordon, a partner at Sygertek, a Montreal-based nanotechnology management consulting firm.
Still, the quality of Nansys' team is not in question. "No doubt there are absolutely brilliant advisers and founders here, both on the technical and the scientific side," Gordon says. "You really can't do any better than [Dr. Charles] Lieber and Bock."
Bock's record is hard to ignore. Of 14 biotechnology companies he has founded, 11 have been acquired or gone public for a total of more than $1 billion, including Caliper Technologies Corp. of Mountain View, Calif., and Illumina Inc. of San Diego.
Lieber, a co-founder, holds the Mark Hyman Chair of Chemistry in the Division of Engineering and Applied Sciences at Harvard University and has won a number of science awards.
Another director is marketing guru Regis McKenna, who helped launch some of the best-known technological innovations of the last 30 years through his work with Intel Corp. of Santa Clara, Calif., Apple Computer Inc. of Cupertino, Calif., and Genentech Inc. of South San Francisco, Calif. Bob Metcalfe, who developed the data-networking technology Ethernet, is also a director.
Sounds good, right? Interested? Well, trying to figure out how to break into the current roster of investors might be a waste of time. "This will be our last venture round until an IPO or some liquidity event," says Stephen Empedocles, co-founder and director of business development of Nanosys.
Of course, startups love to say they're fully funded after closing each new round, but there is some evidence to support Empedocles' claim. Nanosys has already collected around $15 million in government and academic grants; such revenue is part of its business plan. The company also expects to generate revenue by striking more corporate partnerships in the near future as it did with Osaka, Japan-based electronics manufacturer Matsushita Electric Works Ltd. The two companies plan to develop solar cells for the Asian building materials market based on Nanosys' proprietary photovoltaic technology.
Charles Harris, CEO of Harris & Harris Group Inc., says Nanosys is in a unique position to avoid further dilution of existing shareholders by collecting nonequity financing.
"When you've got someone like Larry Bock on board, there's a much better chance for financing to flow from partnerships and grants."
Empedocles stresses that building a strong financial base has been management's intention from the start, and that even before this latest round, the company had nearly $10 million of its previous $17 million round left in the till. So investors not already in the syndicate might be relegated to the sidelines. At least they can take cues from a company that is emerging as the most watched nanotechnology play.
Optionen
Nanotechnologies, Inc. Joint Development and Equity Investment Agreement
Monday June 9, 2:32 pm ET
NEW YORK--(BUSINESS WIRE)--June 9, 2003--Harris & Harris Group, Inc.
announced today that it has invested $169,718 in the Series C Preferred round
financing of Nanotechnologies, Inc. (www.nanoscale.com).
This round of financing included a new investor, Air Products and Chemicals,
Inc. (www.airproducts.com), in addition to previous investors in
Nanotechnologies, Inc., including Harris & Harris Group. Harris & Harris Group
has now invested a total of $919,718 in Nanotechnologies, Inc. and owns a fully
diluted 6.48% interest in Nanotechnologies, Inc.
Nanotechnologies' proprietary pulsed plasma technology produces
high-performance nanoparticles with applications in transparent coatings,
anti-microbial products, and electronic materials, for example. In the past year,
the company has focused on its unique ability to produce metal nanoparticles
such as silver, aluminum and copper.
Optionen
AIR PRODUCTS AND NANOTECHNOLOGIES, INC.
ANNOUNCE JOINT DEVELOPMENT AND EQUITY
INVESTMENT AGREEMENT
LEHIGH VALLEY, Pa./AUSTIN, Tx. (June 9, 2003) — Air
Products and Chemicals, Inc. (NYSE: APD) and
Nanotechnologies, Inc., a technology leader in
high-performance nanoparticles, today announced a joint
development agreement and an equity investment, made by
Air Products in Nanotechnologies, to allow for exclusive
commercial development efforts in select strategic market
segments.
Nanotechnologies' proprietary pulsed plasma technology
produces high performance nanoparticles with applications
in transparent coatings, anti-microbial products, and
electronic materials, for example. In the past year, the
company has focused on its unique ability to produce metal
nanoparticles such as silver, aluminum and copper.
"Nanoparticles are a key enabling technology to many current
and future Advanced Materials product platforms. We chose
to work with Nanotechnologies because of its unique
process, which produces outstanding metal and metal oxide
nanoparticles. Their technology is scalable and economical
and provides great potential value for Air Products' targeted
high growth markets in our Performance Materials Division,"
said Jeffrey T. DePinto, business development manager for
Nanotechnology Strategies at Air Products.
Randy Bell, Nanotechnologies president and CEO stated,
"We are excited at the opportunity to work with
Air Products. We believe that the combined nanomaterials
and formulations expertise of the two companies will
significantly accelerate the development of commercial
applications incorporating our nanoparticles. This
partnership exemplifies our strategy of forming key alliances
with leaders in their respective industries."
About Air Products
Air Products serves customers in technology, energy,
healthcare and industrial markets worldwide with a unique
portfolio of products, services and solutions, providing
atmospheric gases, process and specialty gases,
performance materials and chemical intermediates. The
company is the largest global supplier of electronic materials,
hydrogen, helium and select performance chemicals.
Founded in 1940, Air Products is recognized for its
innovative culture, operational excellence and commitment to
safety and the environment. With annual revenues of
$5.4 billion and operations in over 30 countries, the
company's 17,200 employees build lasting relationships with
their customers and communities based on understanding,
integrity and passion. For more information, visit
www.airproducts.com.
About Nanotechnologies, Inc.
Nanotechnologies Inc. was formed in 1999 and is privately
funded. In May 2002, the company closed its second round
with investments from venture capital firms Techxas
Ventures, Castletop Capital, Convergent Investors VI, Harris
& Harris Group, Inc. (NASDAQ:TINY) and Capital
Conceptions. The Air Products investment is part of a new
round of funding for Nanotechnologies, which includes
participation from prior Series A and Series B investors. For
more information, visit www.nanoscale.com.
Optionen
Ich habe nur einen Fond gefunden, der "Nano" in seinem Namen hat. Leider ist von den wirklichen Knallern keiner enthalten:
ACTIVEST LUX NANOTECH - WKN: 661705
Top Holdings:
Aktie 896007 7,10% VEECO INSTRUMENTS INC. SHARES DL -,01 VEO
Aktie 868730 5,10% ASM INTERNATIONAL N.V. SHARES EO 0,04 AVS
Aktie 626079 4,00% AGERE SYSTEMS INC. SHARES DL -,01 AG3
Aktie 920228 3,90% VARIAN INC. SHARES DL -,01 VR1
Aktie 864089 3,40% COHERENT INC. SHARES DL -,01 COI
Aktie 929138 3,30% AGILENT TECHNOLOGIES INC. SHARES DL -,01 AG8
Aktie 909698 3,00% HEADWATERS INC. SHARES DL -,001 CV6
Aktie 902316 2,80% FEI CO. SHARES DL -,01 FE2
Aktie 853906 2,80% XEROX CORP. SHARES DL 1 XER
Ich plane nach der nächsten überfälligen Korrektur und bei noch starkem Euro ungefähr 15-20% meines Depots in Nanotechnologie zu investieren. Es sollten ausnahmslos US- Werte sein, die außerdem sehr risikoreich und somit chancenreich sind. Mir interessieren keine Firmen, die eine riesen Cashkuh im Hintergrund haben und wo die Nanotechnologie nur im Hintergrund läuft.
Da das Risko gestreut werden soll, würde ich gerne 6-12 Firmen aufnehmen. Deshalb auch die Frage nach Fonds oder Zertis, die sich mit meinen Interessen decken. Wenn es sowas nicht gibt, muss ich halt meinen eigenen Korb zusammenstellen. Ne gute handvoll ist ja in diesem Thread schon aufgeführt.
Beste Grüße
Boxenbauer Optionen
Reine Nanotechunternehmen sind zumeist noch nicht börsennotiert oder haben zumindest eine sehr geringe Marktkapitalisierung.
Mein Favorit, wie man unschwer erkennt, ist daher eindeutig TINY. Die sind vorbörslich in etlichen vielversprechenden Unternehmen investiert, von denen bestimmt einige aufgekauft oder an die Börse gebracht werden. Durch die Streuung kann auch der eine oder andere Flop verkraftet werden. Das Management scheint, soweit ich das beurteilen kann, auch seriös zu sein.
Optionen
ua hier
http://www.stockupticks.com
oder hier
http://www.smallcapmarketwatch.com/
Optionen
| Antwort einfügen |
| Boardmail an "hjw2" |
|
Wertpapier:
Veeco Instruments Inc
|
Wer hier Rechtschreibfehler findet, darf sie behalten!
Optionen
| Antwort einfügen |
| Boardmail an "clip" |
|
Wertpapier:
Veeco Instruments Inc
|
Die nächste Gruppe des Fonds wurde unter dem Namen "Dünnschichtfilme" zusammengefasst (ca. 12% Depotanteil).
In die Gruppe der "Displaytechnologien" (ca. 11% Depotanteil) wurden Firmen zusammengefasst, welchen wir hohes Innovationspotential bei der Entwicklung neuer Displaytechnologien zugestehen.
In die Gruppe "Halbleiter-Technologie" (Depotanteil ca. 9%) wurden zum einen "klassische" Halbleiter-Firmen aufgenommen, die wir als technologisch führend beim Entwickeln kleinerer nanoskaliger Strukturen einstufen, zum anderen Firmen, welche wir als Vorreiter ansehen beim Entwickeln mikro-/nanoskaliger Sensoren.
Die Gruppe der "Diversifizierten Big Caps" (ca. 20% Depotanteil) dient in gewisser Weise der Abrundung des Depots. Es wurde hierbei jedoch Wert darauf gelegt, nur Titel aufzunehmen, bei denen wir zumindest in Zukunft eine signifikante Wertschöpfung über Nanotech-Aktivitäten erwarten.
In die Gruppe der Biotechs (ca. 7% Depotanteil) wurden Werte aufgenommen, welche in den Bereichen der Bioanalytik tätig sind, auch in den Bereichen der DNS-/Proteinanalyse.
Es mag vielleicht überraschen, dass die Gruppe der "Nano-Grundrohstoffe" bzw. "Nanopartikel" mit 1% Depotanteil eine wohl fast vernachlässigbare Größe darstellt. Wir sind jedoch der Ansicht, dass auf mittel- bis langfristige Sicht die bei weitem größere Wertschöpfung denjenigen Firmen zugute kommen wird, welche aus den Grundrohstoffen weitergehende Nanosysteme/nanostrukturierte Materialien entwickeln (wie z.B. Displays, Nanofilter, nanostrukturierte Oberflächen u.a.)
http://www.activest.de/de/home/index.jhtml?pageId=3011&wkn=661705
ist ja vielleicht auch ne Alternative
Optionen
Milliarden für die Nanotechnologie
Weltweit werden in diesem Jahr 3 Milliarden US-Dollar staatliche Gelder in Forschung und Entwicklung von Nanotechnologie gesteckt. Dies berichtet Lux Capital im Nanotech Report 2003. Lux Capital ist eine Investmentfirma, die sich auf Nanotechnologie spezialisiert hat. Der Branche wird von Analysten eine gloriose Zukunft vorhergesagt, doch sie befindet sich noch im Anfangsstadium. Bislang investieren die meisten beteiligten Firmen in die Forschung und kooperieren dabei mit Universitäten. Erst im Laufe der kommenden 10 oder 20 Jahre würden beispielsweise Chips auf Molekularebene auf den Markt kommen.
In vielen Industrienationen werden die Fördermittel für Nanotechnologie ständig angehoben. Die US-Regierung förderte den Forschungszweig seit dem Jahr 2000 mit 2 Milliarden US-Dollar und plant für die kommenden drei Jahre mit einem Etat von 2,36 Milliarden US-Dollar. Die Europäische Union will in den Jahren 2002 bis 2006 rund eine Milliarde US-Dollar in diesen Bereich stecken. In Japan stieg der jährliche Etat für Nanotechnologie-Forschung von 120 Millionen US-Dollar im Jahr 1997 auf 750 Millionen US-Dollar im vergangenen Jahr. Private Investoren steckten seit 1999 rund 900 Millionen US-Dollar in Nanotechnologie-Unternehmen; allein im vergangenen Jahr waren es 386 Millionen US-Dollar. Es gebe mehr als 700 Unternehmen, die sich in diesem Bereich engagieren, beschreibt der Nanotech Report. (anw/c't)
Q: http://www.heise.de/newsticker/data/anw-26.06.03-001/
Gr. luki2
Optionen
Optionen
| Antwort einfügen |
| Boardmail an "kant" |
|
Wertpapier:
Veeco Instruments Inc
|
THURSDAY, JUNE 26, 2003 7:00 AM
- PR Newswire
SUNNYVALE, Calif., Jun 26, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cepheid (CPHD) , today announced that it has been issued U.S. Patent No. 6,565,815. This patent covers aspects of the optical detection system used by Cepheid in its Smart Cycler(R) and GeneXpert(R) systems for the rapid detection and assessment of genetic targets.
The heart of Cepheid's technology for the amplification and real-time detection of nucleic acids is the I-CORE(R) (Integrated, Cooling/heating Optical Reaction) module. The optics incorporated in the I-CORE module allow the system to efficiently and accurately detect multiple DNA sequences simultaneously in a single reaction chamber. Over 19,000 I-CORE modules, assembled into over 1,200 random access Smart Cycler instruments, have been shipped throughout the world since the product was introduced in 2000. The I-CORE module allows practitioners in the fields of Life Sciences Research, Clinical Genetic Assessment and BioThreat Detection to rapidly analyze and detect DNA and other genetic targets using PCR or other nucleic acid amplification chemistries. Key benefits of the I-CORE technology were recently highlighted with Cepheid's announcement of a $175 million contract award to Northrop Grumman by the United States Postal Service for a biohazard detection system, which uses the GeneXpert technology.
"This new patent covers important aspects of Cepheid's system platforms for rapid genetic assessment," said Kurt Petersen, Ph.D., Cepheid's President and Chief Operating Officer. He added, "Cepheid's innovative staff has greatly advanced the state-of-the-art in enabling genetic assessment to be implemented on a broadly disseminated basis."
Cepheid's intellectual property portfolio also includes 9 additional issued patents covering other aspects of its instrument, test cartridge and assay technologies.
Optionen
 | |||
| |||
|
Optionen
| Antwort einfügen |
| Boardmail an "hjw2" |
|
Wertpapier:
Veeco Instruments Inc
|
oxide nanomaterials. The new bismuth oxide product is produced using NanoArc(TM)
Synthesis technology, the Company's most advanced nanomaterials manufacturing
process. Bismuth oxide is incorporated into specialty polymers and materials for
bone implants, dental prosthetic devices, catheters, sutures and surgical
instruments to make them detectable by X-rays without the toxicity or
carcinogenicity associated with other heavy metals. When incorporated into other
plastics, benefits such as X-ray detection of toys and objects swallowed by
children, or X-ray detection of plastic firearms at airport security stations,
can be achieved.
Bismuth oxide has been used extensively for years in the medical
appliance industry to impart X-ray opacity. As parts become smaller and thinner,
it is difficult to incorporate bismuth oxide to achieve X-ray opacity without
deteriorating the physical properties of the plastic or composite part. Because
nanoparticles are so small, they can be incorporated at levels that provide the
needed X-ray opacity without significantly effecting rheology, physical
properties or surface characteristics."
Fahnenstange !ist wieder auf meine Watchlist gerückt...
Optionen
Nantero, Inc. Announces $10.5MM in Funding
Monday September 8, 9:02 am ET
Developing Nanotube-Based Nonvolatile RAM Technology for
Licensing
WOBURN, Mass., Sept. 8 /PRNewswire/ -- Nantero, Inc., a company that is currently
developing NRAM(TM), a high-density nonvolatile random access memory chip using
nanotechnology, announced today that it received its second round of investment. The new lead
investor was Charles River Ventures (www.crv.com), a firm with over 30 years of experience in
high technology. Returning existing institutional investors include Draper Fisher Jurvetson,
based in Redwood City, California, along with Stata Venture Partners and Harris & Harris Group
(Nasdaq: TINY - News). Bruce Sachs and Bill Tai, both Partners at Charles River Ventures,
have joined Nantero's Board of Directors.
Nantero's NRAM(TM) will replace all existing forms of memory, such as DRAM, SRAM and
flash memory, with a high-speed high-density nonvolatile RAM -- 'universal memory.'
NRAM(TM) can simultaneously achieve speeds competitive with SRAM, densities competitive
with DRAM, and also offer the nonvolatility of flash with lower power consumption and unlimited
endurance.
The company will offer for license a complete package to enable manufacturers to produce,
market, and sell NRAM(TM) for both standalone and embedded memory applications. This
technology transfer package will include a process module and the associated process
knowledge, intellectual property rights, and the necessary nanotube materials.
Recently Nantero has created multiple prototype devices, including an array of ten billion
suspended nanotube junctions on a single silicon wafer. Nantero's design for NRAM involves
the use of suspended nanotube junctions as memory bits, with the "up" position representing
bit zero and the "down" position representing bit one. Bits are switched between states through
the application of electrical fields. The wafer was produced using only standard semiconductor
processes, maximizing compatibility with existing semiconductor factories. Bruce Sachs, a
partner with Charles River Ventures in the Waltham office, noted that, "Nantero has achieved
impressive milestones over the last two years, especially in demonstrating compatibility of its
manufacturing process with industry standards."
Bill Tai, a partner in the Silicon Valley office of Charles River Ventures said, "Universal memory
has been a dream for the semiconductor industry for decades-we feel that Nantero's innovative
approach using carbon nanotubes and a nanoelectromechanical design can make that dream a
reality in the near term."
Greg Schmergel, Nantero's co-founder and CEO, commented, "We are pleased to have
completed this round of funding and to have Bruce Sachs and Bill Tai joining us as we move
into the next phase of development for NRAM(TM)."
About Nantero, Inc.
Nantero is currently developing NRAM(TM) -- a high-density nonvolatile random access memory
chip using nanotechnology. NRAM(TM) will replace all existing forms of memory, such as
DRAM, SRAM and flash memory, with a high-density nonvolatile RAM -- 'universal memory.'
The potential applications for the nonvolatile RAM Nantero is developing add up to over $100B
in revenue potential, including the ability to enable instant-on computers and to replace flash
memory in devices such as MP3 players, digital cameras, and PDAs, as well as applications
in the networking arena. For more information on Nantero, Inc. please visit www.nantero.com
Optionen
MONDAY, SEPTEMBER 08, 2003 7:00 AM
- PR Newswire
SUNNYVALE, Calif., Sep 8, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cepheid (CPHD) today announced that it has received a purchase order from the Food and Drug Administration (FDA) for the purchase of sixteen Cepheid Smart Cycler(R) II processing blocks to be utilized with basic Smart Cycler II starter systems for general use in the food safety testing program.
"It is gratifying to see the benefits provided by the Smart Cycler in these important programs. We look forward to doing our best to support these and similar programs with our systems capability that enables genetic evaluation of specimens when and where is it most needed," stated John Bishop, Cepheid's Chief Executive Officer.
Smart Cyclers are currently being used in approximately 60% of the state public health laboratories. The Smart Cycler allows labs to detect pathogens of interest in as little as 25 minutes or less. The Smart Cycler II's rapid thermal cycling, random access (ability to test different pathogens simultaneously) and multiplex capabilities provide key benefits for making the Smart Cycler II a system of choice for major organizations.